Credit Agricole Atlantique Vendee (XPAR:CRAV) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


XPAR:CRAV Credit Agricole Atlantique Vendee XPAR:CRAV
37 GF Score
Price €152.72
GF Value €89.73
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Credit Agricole Atlantique Vendee Research & Development?

Credit Agricole Atlantique Vendee XPAR:CRAV -3.10% 37 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates XPAR:CRAV with a GF Score™ of 37/100 and a GF Value™ of €89.73 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Credit Agricole Atlantique Vendee's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Credit Agricole Atlantique Vendee  (XPAR:CRAV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Credit Agricole Atlantique Vendee Research & Development Related Terms

Credit Agricole Atlantique Vendee Research & Development Historical Data

* Premium members only.

The historical data trend for Credit Agricole Atlantique Vendee's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Credit Agricole Atlantique Vendee Research & Development Chart

Credit Agricole Atlantique Vendee Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Credit Agricole Atlantique Vendee Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:CRAV
37GF Score
Credit Agricole Atlantique Vendee XPAR:CRAV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Credit Agricole Atlantique Vendee Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Credit Agricole Atlantique Vendee (XPAR:CRAV) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Credit Agricole Atlantique Vendee and its competitors.
Is Credit Agricole Atlantique Vendee's Research & Development too high?
Credit Agricole Atlantique Vendee's current Research & Development is €0.0 Mil. Overall, Credit Agricole Atlantique Vendee has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Credit Agricole Atlantique Vendee's Research & Development compare to competitors?
Credit Agricole Atlantique Vendee's Research & Development of €0.0 Mil can be compared against companies in the Banks industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Banks company?
A good Research & Development depends on the Banks industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Credit Agricole Atlantique Vendee and its competitors. Credit Agricole Atlantique Vendee's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Credit Agricole Atlantique Vendee stock overvalued right now?
Based on GuruFocus' analysis, Credit Agricole Atlantique Vendee (XPAR:CRAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €89.73, compared to a current price of €152.72 — trading 70.2% above its estimated fair value. The current Research & Development is €0.0 Mil. Credit Agricole Atlantique Vendee's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Credit Agricole Atlantique Vendee (XPAR:CRAV), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Credit Agricole Atlantique Vendee (XPAR:CRAV) Overvalued in 2026?

Based on GuruFocus' analysis, Credit Agricole Atlantique Vendee stock appears to be overvalued. The current stock price of €152.72 is trading 70.2% above its estimated GF Value™ of €89.73. GuruFocus considers Credit Agricole Atlantique Vendee to be Significantly Overvalued.

Key valuation signals for XPAR:CRAV:

  • Research & Development: €0.0 Mil
  • GF Value™: €89.73 vs. price of €152.72 (70.2% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the XPAR:CRAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Credit Agricole Atlantique Vendee Business Description

Other Exchanges 0OQK:UK
Address Route de Paris, Nantes, FRA, 44949
Credit Agricole Atlantique Vendee is a regional bank belonging to the Credit Agricole Group. It is engaged in providing banking and insurance solutions in France. It offers its services to individuals, professionals, farmers and companies.
37GF Score

Get the complete analysis for XPAR:CRAV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€152.72
Price
€89.73
GF Value